Diabetic nephropathy (DN) is a serious microvascular complication of both type 1 and type 2 diabetes (T2DM). Elevated urinary albumin excretion and decreased glomerular filtration rate (GFR) are risk factors for cardiovascular morbidity and mortality and progression to end-stage renal failure in individuals with diabetes. End-stage renal disease secondary to DN accounts for ∼50% of cases in most developed countries. The pathogenesis of DN is multifactorial. Familial clustering of DN and related traits such as albuminuria and GFR indicate that genes play a major role in its susceptibility ([@B1]). Despite the recent efforts to identify and characterize DN susceptibility genes, the genes involved in susceptibility to the development and or progression of DN and in particular GFR have yet to be identified.

Equations that estimate GFR facilitate the diagnosis, evaluation, and management of chronic kidney disease. GFR varies between individuals and is influenced by genetic and environmental factors and their interactions. Both genome-wide linkage and association analytical approaches have been used to localize the susceptibility genes/variants that influence variation in GFR ([@B2]--[@B11]). However, the functional significance of the finding from such studies is yet to be explored. To localize genes contributing to variation in GFR, we recently performed a genome-wide linkage screen using GFR data (*N* = 453) from the Mexican American participants of the San Antonio Family Diabetes/Gallbladder Study (SAFDGS) and identified the strongest linkage of GFR to occur on chromosome 2q35--37 near the markers *D2S1363-D2S427* (LOD = 3.8; LOD~c~ = 3.3) after incorporating genotype by environment (T2DM) interaction effects ([@B5]). Identification of linkage of GFR on 2q is detailed in the [Supplementary Data](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-1078/-/DC1). We hypothesize that there is a gene(s) located on chromosome 2q35--37 that may be related to the linkage signal identified.

Of the positional candidate genes in the critical interval, *IRS1* gene is located 200 kb telomeric to the marker *D2S1363*. When phosphorylated, IRS1 acts as a docking protein for multiple Src homology-2 (SH2)--containing proteins such as phosphatidylinositol-3-kinase (PI3K), growth factor receptor--binding protein-2, and tyrosine phosphatase SHP2. These proteins in turn further activate downstream effectors that mediate the biological effects of insulin in several tissues including kidney ([@B12],[@B13]). Mice deficient in IRS1 by targeted disruption of its gene display insulin resistance and impaired glucose tolerance ([@B14]), and mice heterozygous for defects in genes for both *IRS1* and the insulin receptor ([@B15]) or *IRS1* and glucokinase ([@B16]) develop overt diabetes. Genetic variation in *IRS1*, particularly Gly(972)Arg (rs1801278) variant, plays a contributory role in insulin resistance and diabetes susceptibility ([@B17]) probably through impaired insulin receptor signaling ([@B18]--[@B20]). Genetic variants (rs2943641; rs2943650) located 500 kb upstream of *IRS1* were recently reported to be associated with insulin resistance, hyperinsulinemia, dyslipidemia, and T2DM ([@B21],[@B22]).

Given the functional significance of IRS1 together with our finding that it is a positional candidate gene in the GFR linkage region on chromosome 2q, we determined whether genetic variation in the *IRS1* gene contributes to variation in GFR in the Mexican American participants of SAFDGS.

RESEARCH DESIGN AND METHODS {#s1}
===========================

The SAFDGS family member recruitment and data collection procedures were reported previously ([@B23]). In brief, probands were Mexican Americans with T2DM with low income, and all first-, second-, and third-degree relatives of probands were invited to participate in the study. A variety of metabolic, hemodynamic, anthropometric, and demographic variables were collected from about 700 individuals drawn from 39 large Mexican American families. Diabetes status was defined by the 1999 criteria of the World Health Organization (i.e., fasting glucose levels ≥126 mg/dL and/or 2-h glucose levels ≥200 mg/dL).

Of the individuals examined at SAFDGS, GFR data were available for 453 individuals distributed across 29 families. GFR values were estimated as described previously ([@B5]) by the two recently recalculated GFR prediction equations ([@B24]): the recalculated simplified four-variable Modification of Diet in Renal Disease (GFR-MDRD) study equation ([@B25]) and the Cockcroft-Gault (GFR-CG) equation ([@B26]) adjusted for body surface area and corrected for the bias in the MDRD data. The quantitative trait values of triglycerides (TGL) and albumin-to-creatinine ratio were log transformed and used in the association analyses since their raw data were nonnormally distributed. The Institutional Review Board of the University of Texas Health Science Center at San Antonio approved all procedures, and all subjects gave informed consent.

Molecular variants identification and genotyping. {#s2}
-------------------------------------------------

Exons and 2-kb putative promoter region of *IRS1* gene were screened for DNA sequence variants in 32 individuals, who contributed positively to the linkage, by direct sequencing of PCR products amplified from genomic DNA isolated from peripheral blood leukocytes. Oligonucleotide primers used for PCR and sequencing are available upon request. Sequencing was performed using ABI Prism Big Dye Terminator Cycle Sequencing kit (Applied Biosystems \[ABI\]) and a capillary sequencer (Model 3730xl; ABI). Genotyping of all the SNPs was performed using the TaqMan assay (ABI), which was carried out on a GeneAmp PCR system 9700 (ABI), and fluorescent signals were detected on an ABI PRISM 7700 sequence detector (ABI). To assure accuracy of the genotyping, coded blind replicate samples from 50 subjects were included in each assay.

Statistical genetic analysis. {#s3}
-----------------------------

The genotypic data were checked for Mendelian consistency using the program SimWalk2 ([@B27]). All polymorphisms were tested for Hardy-Weinberg Equilibrium. Allele frequencies were estimated using maximum likelihood techniques, which account for pedigree structure. Linkage disequilibrium (LD) between SNPs was estimated using the *r*^2^ values. We performed association analysis in our complex pedigree-based data using the measured genotype approach (MGA) within the variance components (VC) analytical framework ([@B28],[@B29]). The VC-based approach accounts for the nonindependence among family members. In this analytical technique, VCs are modeled as random effects (e.g., additive genetic effects and random environmental effects), whereas the effects of measured covariates such as age and sex are modeled as fixed effects on the trait mean. The marker genotypes were incorporated in the mean effects model as a measured covariate, assuming additivity of allelic effects ([@B28]--[@B30]). The effect of this measured genotype (i.e., association parameter) together with other covariate effects and VCs were estimated by maximum likelihood techniques. For association analysis between genotypes and GFR, age and sex terms in addition to other covariates were used in consideration of both biological and/or statistical significance. For GFR-CG analysis, age, age^2^, sex, diabetes, duration of diabetes, systolic blood pressure (SBP), and antihypertensive medications were used as covariates. For GFR-MDRD, age, sex, BMI, diabetes, duration of diabetes, SBP, and antihypertensive medications were used as covariates.

The hypothesis of no association is tested by comparing the likelihood of a model in which the effect of the measured genotype is estimated with a model where the effect of the measured genotype was fixed at zero. Twice the difference in the log-likelihoods of these models yields a test statistic that is asymptotically distributed, approximating a χ^2^ distribution with one degree of freedom. Before MGA was performed, the quantitative transmission disequilibrium test ([@B31]) was used to examine hidden population stratification. Given the LD patterns among the examined 13 SNPs, we obtained a *P* value after adjusting for multiple testing using an effective number of SNPs calculated following the method of Li and Ji ([@B32]). For a statistical threshold of ≤0.05, the required experiment-wide significance threshold, using the effective number of SNPs (which was 7.66) to adjust for multiple testing was 0.00667. Because the issue of correction for multiple testing is not straight forward with regard to multiple correlated traits, there were no additional attempts to correct for multiple testing because the corresponding models are not independent. All statistical techniques described above were implemented in the computer program SOLAR.

The Bayesian quantitative trait nucleotide (BQTN) analytical technique was used to analyze the *IRS1* SNP and GFR data further, with the use of the program SOLAR. This technique has been detailed elsewhere ([@B33]). Given complete SNP data for a gene, this statistical technique can be used to identify the sequence variants that are either potentially functional or that exhibit the highest disequilibria with such potential functional sites. The BQTN model is a simple extension of the classical variance component model, which aims to disentangle the genetic architecture of a quantitative trait. Because a candidate gene may contain a number of SNPs that could generate several possible competing models of quantitative trait nucleotide (QTN) action, we used a Bayesian model selection/model averaging approach to analyze the SNP data simultaneously to estimate the probability that each SNP has a direct effect on the phenotype ([@B33],[@B34]).

To determine whether the associated SNP(s) found by the QTN analysis can account for our reported linkage of GFR at chromosome 2q35--37, we combined the QTN analysis with our identity-by-descent--based variance component linkage analysis. If a variant, or set of variants, in the *IRS1* gene contributes to the observed linkage signal, linkage analysis conditional on a fixed effect, MGA of the polymorphism will yield a LOD score near zero. Alternatively, if the associated polymorphism is in less than complete LD with the true functional site, linkage analysis will yield a reduced, but nonzero LOD score. This method has been described in detail elsewhere ([@B29]).

Western blot analysis. {#s4}
----------------------

The plasmids carrying *IRS1* gene with glycine at codon 972 (wild type) and arginine at codon 972 (mutant) were provided by Dr. Sesti ([@B35]). Plasmids were transfected into human kidney mesangial cells using the FuGene HD transfection reagent as recommended (Roche Diagnostics). Cells (90--95% confluence) were washed twice with PBS, and media were replaced with 0.45 mL of OPTI-MEM I (Invitrogen). Precomplex of the plasmid DNA (0.5 μg/well) with FuGene (0.5 μL/well) in Opti-MEM was mixed (50 μL/well) and incubated at room temperature for 5 min. DNA and FuGene complexes were added to each well and incubated at 37°C with 5% CO~2~. Cells were then incubated for 6 h followed by addition of 0.5 mL of fresh media with 34% serum to a final concentration of 17%. After 48 h of transfection, cells were made quiescent by serum deprivation for 24 h, followed by treatment with insulin (100 μM) for 0, 5, and 10 min. Cells were harvested and lysed with radioimmunoprecipitation assay buffer. Equal amounts of total cellular proteins were fractioned by SDS--polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes, and probed with the following antibodies: anti-IRS1 (Upstate), antiphospho-IRS1 (Tyr 941) (Santa Cruz), anti-Akt, antiphospho-Akt (Thr 308) (Cell Signaling), and antiactin (Sigma). Bound antibodies were visualized using SuperSignal West Pico kit (Thermo Scientific). Densitometric analysis was performed using the National Institutes of Health ImageJ program.

RESULTS {#s5}
=======

The clinical characteristics of the study participants are shown in [Table 1](#T1){ref-type="table"}. Of the genotyped individuals, the available phenotypic data for each phenotype varied from 610 subjects for total cholesterol to 670 subjects for age. In the total sample, 29, 28, and 14% of the subjects had hypertension, T2DM, and albuminuria, respectively ([Table 1](#T1){ref-type="table"}). However, the GFR data were available for only 453 subjects. Of the individuals with GFR data, 29% had T2DM.

###### 

Clinical characteristics of the genotyped SAFDGS participants used for the current study^a^

![](2385tbl1)

*IRS1* (NM_005544) is composed of two exons, and the full-length protein is encoded by exon-1 ([Fig. 1](#F1){ref-type="fig"}). To identify DNA polymorphisms in *IRS1*, we sequenced both exons and 2-kb putative promoter region of *IRS1* in 32 subjects who contributed positively to the linkage of GFR. In total, we identified 11 SNPs including seven in the coding region, and two each in the 3′ UTR and putative promoter regions ([Fig. 1](#F1){ref-type="fig"}). Of the seven SNPs identified in the coding region, five are synonymous (Asp90Asp, Gly234Gly, His400His, Ala804Ala, Pro893Pro) and two are nonsynonymous SNPs (Pro512Ala, Gly(972)Arg). In addition, we chose eight tagging SNPs (SNPs-10--16, 19) from HapMap database for the analysis to comprehensively cover ∼59-kb-long region of intron 1 of *IRS1* ([Fig. 1](#F1){ref-type="fig"}). All the 19 SNPs (11 identified by resequencing and 8 from the public database) shown in [Fig. 1](#F1){ref-type="fig"} (SNP-1 to SNP-19) were genotyped in the entire data set (*N* = 670; 39 families) by TaqMan assay.

![Schematic diagram of human *IRS1* (NM_005544) gene structure on 2q36 and the location of the SNPs identified and genotyped in SAFDGS. The exons of the *IRS1* are represented by solid box and the intron by a thin line. SNPs with the base change and their reference sequence (rs) numbers are indicated by the vertical arrow.](2385fig1){#F1}

Based on the genotypic data, six were excluded from further analysis because one (SNP-7) failed to be in Hardy-Weinberg Equilibrium and the minor allele frequencies of five SNPs (SNPs-5, 6, 8, 17, and 18) were less than 0.5% ([Fig. 1](#F1){ref-type="fig"}). We estimated the pairwise LD (*r*^2^) between all the 13 SNPs and found that the pairwise LD ranged from 0 to 1.0 ([Fig. 2](#F2){ref-type="fig"}). As can be seen from [Fig. 2](#F2){ref-type="fig"}, the relatively high pairwise LDs (*r*^2^ \> 0.8) were found for the following SNPs pairs: rs2234931-rs1801278 (*r*^2^ = 1.0), rs2288586-rs10498212 (*r*^2^ = 0.97), rs4675093-rs10205923 (*r*^2^ = 0.92), rs12052364-rs10181778 (*r*^2^ = 0.88), and rs12052364-rs11690232 (*r*^2^ = 0.84).

![LD between SNP pairs within the *IRS1* gene. SNPs are labeled on the *y*-axis, and the locations (bp) within the gene are shown on the *x*-axis. Pairwise LD is estimated using *r*^2^ values and depicted in the figure by the color intensity of the shaded box, as shown in the legend. The diagonal represents a comparison of each SNP against itself (i.e., *r*^2^ = 1.0). (A high-quality color representation of this figure is available in the online issue.)](2385fig2){#F2}

Association analysis between genotypic and GFR data were performed using MGA. The β-coefficients and *P* values of the covariates used are given in the [Supplementary Data](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-1078/-/DC1). The location, allele frequencies, and association analyses of 13 SNPs are summarized in [Table 2](#T2){ref-type="table"}. Of the 13 SNPs examined for association, the G to A substitution at codon 972 changing the amino acids from Glycine to Arginine (Gly(972)Arg) with minor allele frequencies of about 4% was found to be significantly associated with GFR-CG (*P* = 0.0006). Given the sample size of 431 for this analysis ([Table 2](#T2){ref-type="table"} and [Table 3](#T3){ref-type="table"}), genetic effects that account for 2.9% of the total phenotypic variation in GFR-CG could be detected with 80% power with an experiment-wide *P* value \< 0.05 (i.e., effective number of SNPs = 7.66). In this study, the Gly(972)Arg polymorphism explains 3.3% of the phenotypic variation in GFR-CG. The Gly(234)Gly (rs2234931), which was in complete LD (*r*^2^ = 1; [Fig. 2](#F2){ref-type="fig"}) with Gly(972)Arg variant (rs1801278) also exhibited similar association with GFR. The Gly(972)Arg and Gly(234)Gly variants were also found to be significantly associated with GFR-MDRD (*P* = 0.0046) ([Table 2](#T2){ref-type="table"}). These associations continue to be significant after adjusting for multiple testing. It should be noted that no individuals were homozygous for the rare allele in either of these SNPs.

###### 

Association analysis between the *IRS1* polymorphisms and GFR and T2DM-related traits

![](2385tbl2)

###### 

Mean values of GFR by Gly(972)Arg genotype categories

![](2385tbl3)

Subsequently, we conducted BQTN analysis with eight SNPs, after excluding five SNPs (SNP-4-rs2234931; SNP-12-rs10498212, SNP-15-rs10205923, SNP-16-rs10181778, SNP-19-rs11690232) that exhibited redundancy owing to relatively high pairwise LD (*r*^2^ \> 0.80) ([Fig. 1](#F1){ref-type="fig"} and [Fig. 2](#F2){ref-type="fig"}). Of the eight SNPs, SNPs 1--3, 9--11, 13, and 14 resulted in the examination of 256 plausible additive gene action models; the Gly(972)Arg variant provided strongest evidence for the observed association with GFR-CG, with estimated posterior probability of \>0.99 (data not shown). Such a high posterior probability of effect is suggestive of a direct functional effect for this variant. As revealed by the MGA, the mean GFR values by genotypic categories differed significantly ([Table 3](#T3){ref-type="table"}). The carriers of Arg972 variant had significantly decreased GFR-CG and GFR-MDRD values.

To determine whether Gly(972)Arg could account for the initial linkage signal, we performed linkage analysis on chromosome 2 conditional on the measured genotype effect. Because the sample size available (*N* = 431) for the Gly(972)Arg genotypic data was slightly smaller than the sample size (*N* = 453) used for the original linkage study ([@B5]), we repeated the linkage analysis of GFR-CG with genotype-by-diabetes interaction influences. As was done in our original linkage report ([@B5]), the LOD score obtained from the linkage analysis was adjusted with 2df to 1df, denoted as LOD~c~ score. More details on the adjustment of 2df to 1df are provided in the [Supplementary Data](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-1078/-/DC1). The LOD~c~ obtained in the current study was 3.1 (*N* = 431) compared with the original report of 3.3 (*N* = 453). By inclusion of the Gly(972)Arg polymorphism in the model, the LOD~c~ score went down from 3.1 to 2.3; thus, about 26% of the evidence for linkage of GFR at 2q was explained by this variant ([Fig. 3](#F3){ref-type="fig"}). Taken together, these data suggest that the Gly(972)Arg contribute to the decrease in GFR and that Gly(972)Arg may be one of the several potential functional sites regulating GFR or it is in LD with the true functional variant(s) in *IRS1* or genes flanking *IRS1*.

![Linkage analysis conditional on the Gly(972)Arg polymorphism on chromosome 2q.](2385fig3){#F3}

To further determine the functional mechanism by which Arg972 of variant of *IRS1* may contribute to variation in GFR, we transfected the human renal mesangial cells with the expression vector pcDNA3 carrying wild-type (Gly972) and mutant (Arg972) IRS1 ([@B35]) and studied their effect on the insulin-induced tyrosine (941) phosphorylation of IRS1 and threonine (308) phosphorylation of Akt kinase, a critical downstream effector of PI 3-kinase. Transfected cells were treated with 100 nmol/L insulin for 0, 5, and 10 min and lysed. Equal amount of total proteins were subjected to SDS-PAGE and probed with the following antibodies: anti-IRS1, antiphospho-IRS1, anti-Akt, antiphospho-Akt, and actin. In cells expressing Arg972 variant of IRS1, insulin-stimulated phosphorylation of IRS1 was significantly decreased by 57.3% at 5 min and by 65.8% at 10 min of insulin treatment compared with cells expressing Gly972 variant of IRS1 ([Fig. 4*A*](#F4){ref-type="fig"}). Compared with cells expressing Gly972 variant of IRS, insulin-induced Thr308-Akt phosphorylation was also significantly reduced in cells expressing Arg972 variant of IRS1 by 75.9% at 5 min and by 88% at 10 min of insulin treatment ([Fig. 4*B*](#F4){ref-type="fig"}).

![Effect of Arg972 on the insulin-induced phosphorylation of IRS1 and Akt in human mesangial cells. *A*: Tyrosine (941) phosphorylation of IRS1. Human mesangial cells were transfected with plasmids carrying wild type (WT; Gly972) and mutant (Mut; Arg972) *IRS1* and treated with 100 nM insulin for 0, 5, and 10 min. Equal amount of total cellular proteins were separated on SDS-PAGE gel and probed with anti-IRS1 and antiphospho-IRS1. *B*: Threonine (308) phosphorylation of Akt kinase. Human mesangial cells were transfected with plasmids carrying wild-type (Gly972) and mutant (Arg972) *IRS1* and treated with 100 nM insulin for 0, 5, and 10 min. Equal amount of total cellular proteins were immunoprecipitated with anti-Akt kinase and separated on SDS-PAGE gel and probed with anti-Akt and antiphospho-Akt kinase. Representative images of three independent experiments are shown.](2385fig4){#F4}

Association analysis was also extended to available phenotypic data including SBP, diastolic blood pressure (DBP), TGL, HDL-cholesterol (HDL-C), albumin-to-creatinine ratio, and T2DM. It is noteworthy that the two variants \[Gly(972)Arg and Gly(234)Gly\] that exhibited significant associations with the GFR measures were also found to be significantly associated with TGL (*P* = 0.0033) ([Table 2](#T2){ref-type="table"}). In addition, a promoter variant of *IRS1* (SNP-2; rs6436635) with minor allele frequency of 10.1% was significantly associated with TGL (*P* = 0.0328), SBP (*P* = 0.0007), and DBP (*P* = 0.0023) ([Table 2](#T2){ref-type="table"}). In addition, a promoter variant (SNP-1) with a minor allele frequency of 2.6% and a synonymous variant (SNP-3; Asp90Asp) with minor allele frequency of 3.8% also showed statistically significant association with HDL-C (*P* = 0.0444 and *P* = 0.0386, respectively). A pair of intronic region SNP (rs4675093-rs10205923), which were in strong LD (*r*^2^ = 0.92), also exhibited significant association with SBP (*P* = 0.0025 and 0.0085, respectively). These SNPs also showed suggestive association with HDL-C ([Table 2](#T2){ref-type="table"}).

DISCUSSION {#s6}
==========

There is a large interindividual variation in GFR in patients with diabetes and in the general population. It is known that variation in GFR is influenced by environmental and genetic factors as well as their interactive influences ([@B2]--[@B11]). In an effort to identify and characterize GFR susceptibility gene(s), we localized a genetic region on chromosome 2q35--37 that exhibited linkage to GFR ([@B5]). As we report in this study, this locus, which does not confer susceptibility to T2DM ([@B5]), exerts a differential influence on GFR in diabetic and nondiabetic individuals. Of the positional candidate genes, *IRS1* is a strong susceptibility candidate gene to influence GFR since the IRS1 protein plays a pivotal role in modulating tissue response to insulin including in the kidney. A structural defect in this protein as a result of genetic variation may alter kidney function.

To date, several DNA sequence variants have been identified in human *IRS1*. Of those, the main focus has been on Gly(972)Arg variant, since Almind et al. ([@B36]) first identified this polymorphism to contribute to T2DM in a Danish cohort. Subsequent case control studies in different ethnic groups have examined the association between the Gly(972)Arg variant of *IRS1* and T2DM and related traits. Although the association results have been controversial, a meta-analysis combining 27 studies, which included 3,408 cases and 5,419 control subjects, suggested that the carriers of the Gly(972)Arg variant have a 25% increased risk for developing T2DM ([@B17]). In addition, a marked ethnic difference in the distribution of Gly(972)Arg variant was also observed. The Arg972 variant of *IRS1* was found to be more common in Caucasians (20%) ([@B37]) compared with African Americans (11%) ([@B38]), Asians (4%) ([@B39]), and Mexican Americans (4%) ([@B40]). In this study, we observed a frequency of about 4% for Arg972, which is similar to the one reported in another Mexican American population ([@B40]). Similarly, Gly(972)Arg failed to show an association with T2DM as reported ([@B40]).

Of the 13 SNPs examined for association with GFR, only the Gly(972)Arg variant of *IRS1* exhibited significant association with GFR estimated by two formulae. The BQTN analysis using information from eight nonredundant SNPs also demonstrated that the Gly(972)Arg variant could influence phenotypic variation in the levels of GFR with estimated posterior probability of \>0.99. This high posterior probability effect reflects the potential functional impact of this variant on GFR. It is interesting that the carriers of Arg972 had significantly decreased GFR values. The subsequent conditional linkage/QTN analysis revealed that the Gly(972)Arg variant explained ∼26% of the linkage signal for GFR on 2q. Taken together, our data demonstrate that the Gly(972)Arg variant significantly contributes to decrease in GFR.

The functional mechanism by which Arg972 variant contributes to decline in GFR remains speculative. Several studies have demonstrated that expression of the 972Arg variant of *IRS1* in cultured adipocytes, muscle, and pancreatic b cells caused a defect not only in Tyr-941 phosphorylation of IRS1 but also in binding of the p85 regulatory subunit of PI3K to the IRS1, resulting in a decrease in IRS1-associated PI3K activity and subsequent activation of the Ser/Thr kinase Akt ([@B19],[@B35],[@B41]--[@B44]). Hribal et al. ([@B20]) generated transgenic mice overexpressing Arg972 and confirmed a significant attenuation in insulin signaling pathways downstream of IRS1 in the liver, skeletal muscle, and adipose tissue.

In the current study, we studied the effect of Arg972 on the insulin-stimulated tyrosine phosphorylation of IRS1 and threonine phosphorylation of Akt in human renal mesangial cells. We show that expression of Arg972 in mesangial cells significantly reduces insulin-induced phosphorylation of IRS1 and Akt kinase compared with wild-type controls. Impaired IR/IRS1 signaling in mesangial cells provides a potential mechanism by which Arg972 variant of *IRS1* contributes to decreased GFR. Alterations in the contractile property of mesangial cells as a result of impaired IR/IRS1 signaling by Arg972 variant may lead to alterations in glomerular hemodynamics, thereby influencing GFR. Because insulin has been shown to be a survival factor for mesangial cells ([@B45]), impaired insulin signaling by the Arg972 variant may lead to apoptosis of these cells, thereby contributing to structural changes in the glomerulus resulting in a decrease in surface area available for filtration. Functional studies are necessary to prove the hypothesis that the Arg972 variant of *IRS1* not only impairs IR signaling to protect mesangial cells against apoptosis but also impairs contractile function of mesangial cells. Impaired nitric oxide (NO) production in vascular endothelial cells by the Arg972 variant may also contribute to the decreased GFR. Human umbilical vein endothelial cells isolated from carriers of the Arg972 variant of *IRS1* have impaired eNOS expression in response to insulin ([@B46]). Because the impaired IR/IRS1 signaling is a potential mechanism for the observed association, we also performed association analysis for the 13 SNPs using fasting glucose data (*N* = 541) after excluding T2DM individuals that are on antidiabetic medications. Although the Gly(972)Arg variant failed to show an association, the promoter variant (rs6436635) was found to be nominally associated (*P* = 0.035) with glucose levels.

The present data also show an association of Gly(972)Arg variant with TGL in our cohort, and the carriers of Arg972 had decreased TGL values. Our finding of lower TGL concentrations in carriers of Arg972 contradicts previous observations in other populations at high risk to develop atherosclerotic cardiovascular disease ([@B47],[@B48]). However, our findings are in agreement with others who reported that patients with T2DM ([@B49]) and patients with insulin resistance ([@B50]) have low concentrations of TGL. The functional significance of promoter variants, Asp90Asp, and a pair of intronic variants (rs4675093 and rs10205923) that exhibit an association with cardiovascular risk factors such as HDL-C, TGL, SBP, and DBP in this study remains to be determined.

Despite several strengths, our study has potential limitations. To our knowledge, the two estimates of GFR (GFR-CG and GFR-MDRD) have not been validated in the Mexican American population. Whereas the time-consuming and expensive direct measurement of GFR is difficult to perform (e.g., inulin, iothalamate clearance) in large family studies, the estimated GFR using the abbreviated MDRD and GC formulae has been proposed as the best validated means for transforming serum creatinine measurements into GFR ([@B25],[@B51]) and used in several linkage studies ([@B2]--[@B11]). Another limitation is that because our resequencing effort was based on only 32 individuals, it is possible that we might have missed rare variants specific to this population. However, given the recent emphasis on the role of rare variants in complex disease causation compared with the common variants examined using the genome-wide association studies, it is very interesting to note that the Gly(972)Arg associated with decline in GFR values has a frequency of 4.0%. We tried to replicate the association between Gly(972)Arg variant of *IRS1* and GFR in two independent family studies: the San Antonio Family Heart Study (Mexican Americans, *N* = 844) and the Joslin Study on the Genetics of Type 2 Diabetes (Caucasians, *N* = 825). Unfortunately, we failed to replicate the findings.

In conclusion, we provide evidence for the first time that Arg972 variant of *IRS1* is associated with variation in GFR; carriers of Arg972 had significantly decreased GFR values and Arg972 variant accounts for 26% of the linkage of GFR on 2q37. It is noteworthy that we show that expression of Arg972 in human mesangial cells reduces the insulin-stimulated phosphorylation of IRS1 and Akt kinase. Together, it is possible to speculate that the associated variant is one of multiple potential functional variants influencing variation in GFR in the *IRS1* gene or is in LD with a potential functional variant(s) in the genes flanking *IRS1*. There is evidence for long-range LD in the human genome ([@B52]). However, in the absence of knowledge on such long-range LD of the SNP of interest in this study, it is important to note that genetic variants located 500 kb upstream of *IRS1* were recently shown to be strongly associated with impaired metabolic profiles including insulin resistance and T2DM. Furthermore, these variants also impaired the IR/IRS1 signaling ([@B21],[@B22]). Therefore, a thorough screening of the critical region on 2q37 may identify additional variants that could potentially relate to the GFR linkage finding in this study. Identification of susceptibility genes that contribute to the decline in GFR may facilitate prediction, prevention, and development of improved treatments of this devastating complication of diabetes.

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-1078/-/DC1>.
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